FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285807005> ?p ?o ?g. }

• W4285807005 endingPage "105.e6" @default.
• W4285807005 startingPage "105.e1" @default.
• W4285807005 abstract "To evaluate the feasibility, tolerance and efficacy of cisplatin+capecitabine as a proposed combination in concurrent chemoradiotherapy for patients with muscle-invasive bladder cancer (MIBC).MIBC patients with stage T2-T4aN0M0 participated in this single-arm clinical trial. After maximal TURBT, 66Gy/33 daily fractions of radiation were administered with concurrent chemotherapy of cisplatin (35 mg/m2) and capecitabine (625 mg/m2). The primary endpoint was treatment tolerability, defined as receiving capecitabine+cisplatin combination for at least 5 weeks during radiation therapy. The secondary endpoints included complete response (CR) and acute toxicity rates.This study included 19 MIBC patients from 2018 to 2019. Eighteen patients (94.7%, 95%CI: 75.4-99.0) completed the planned treatment course. Only one patient (5.26%, 95%CI: 0.9-24.6) discontinued the treatment due to grade-3 GI toxicity. Among those who completed the treatment, CR was seen in 12 patients (66.7%, 95% CI = 44.4-88.9) with no grade ≥ 3 toxicities. The most common grade-2 side effects during therapy were renal complications (57.9%), and the only grade-2 complication after therapy was urinary-related (11.1%). The median follow-up was 31 months and the median overall survival (OS) was 31 months. The 2-year OS was 78% (95% CI 58.4-97.6), Cystectomy-free survival was 61% (95% CI: 37.5-84.5), and the median OS after recurrence was 13 months. Distant metastases were the first type of recurrence in most patients with a recurrence, which occurred in 7 (36.8%) patients. Median metastasis-free survival (MFS) was 30 months, and 2-year MFS was 66% (95% CI:45-87).The promising tolerability rate seen with concurrent cisplatin+capecitabine in this study was comparable to the available literature. Thus, this combination concurrently with radiation warrants further studies in the context of chemoradiotherapy of MIBC." @default.
• W4285807005 created "2022-07-19" @default.
• W4285807005 creator A5000996714 @default.
• W4285807005 creator A5009519349 @default.
• W4285807005 creator A5013475678 @default.
• W4285807005 creator A5016551164 @default.
• W4285807005 creator A5021746691 @default.
• W4285807005 creator A5062593753 @default.
• W4285807005 creator A5076793989 @default.
• W4285807005 creator A5091149741 @default.
• W4285807005 date "2023-02-01" @default.
• W4285807005 modified "2023-09-27" @default.
• W4285807005 title "Assessment of Tolerability, Response and Complications of Concurrent Chemoradiation With Capecitabine and Cisplatin in Muscle-Invasive Bladder Cancer; A Single Arm Study" @default.
• W4285807005 cites W1774531900 @default.
• W4285807005 cites W1985950314 @default.
• W4285807005 cites W1992548667 @default.
• W4285807005 cites W2025912784 @default.
• W4285807005 cites W2028522982 @default.
• W4285807005 cites W2066547804 @default.
• W4285807005 cites W2068304535 @default.
• W4285807005 cites W2072167013 @default.
• W4285807005 cites W2072258776 @default.
• W4285807005 cites W2087675944 @default.
• W4285807005 cites W2103492268 @default.
• W4285807005 cites W2107944116 @default.
• W4285807005 cites W2135108459 @default.
• W4285807005 cites W2138312679 @default.
• W4285807005 cites W2139817908 @default.
• W4285807005 cites W2164361265 @default.
• W4285807005 cites W2396366872 @default.
• W4285807005 cites W2586059174 @default.
• W4285807005 cites W2609787832 @default.
• W4285807005 cites W2900683197 @default.
• W4285807005 cites W3090799961 @default.
• W4285807005 doi "https://doi.org/10.1016/j.clgc.2022.07.007" @default.
• W4285807005 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35948483" @default.
• W4285807005 hasPublicationYear "2023" @default.
• W4285807005 type Work @default.
• W4285807005 citedByCount "0" @default.
• W4285807005 crossrefType "journal-article" @default.
• W4285807005 hasAuthorship W4285807005A5000996714 @default.
• W4285807005 hasAuthorship W4285807005A5009519349 @default.
• W4285807005 hasAuthorship W4285807005A5013475678 @default.
• W4285807005 hasAuthorship W4285807005A5016551164 @default.
• W4285807005 hasAuthorship W4285807005A5021746691 @default.
• W4285807005 hasAuthorship W4285807005A5062593753 @default.
• W4285807005 hasAuthorship W4285807005A5076793989 @default.
• W4285807005 hasAuthorship W4285807005A5091149741 @default.
• W4285807005 hasConcept C121608353 @default.
• W4285807005 hasConcept C126322002 @default.
• W4285807005 hasConcept C126894567 @default.
• W4285807005 hasConcept C141071460 @default.
• W4285807005 hasConcept C143998085 @default.
• W4285807005 hasConcept C197934379 @default.
• W4285807005 hasConcept C203092338 @default.
• W4285807005 hasConcept C2775910329 @default.
• W4285807005 hasConcept C2776694085 @default.
• W4285807005 hasConcept C2777909004 @default.
• W4285807005 hasConcept C2778239845 @default.
• W4285807005 hasConcept C2778375690 @default.
• W4285807005 hasConcept C2778424827 @default.
• W4285807005 hasConcept C2778715236 @default.
• W4285807005 hasConcept C2780352672 @default.
• W4285807005 hasConcept C509974204 @default.
• W4285807005 hasConcept C526805850 @default.
• W4285807005 hasConcept C535046627 @default.
• W4285807005 hasConcept C71924100 @default.
• W4285807005 hasConceptScore W4285807005C121608353 @default.
• W4285807005 hasConceptScore W4285807005C126322002 @default.
• W4285807005 hasConceptScore W4285807005C126894567 @default.
• W4285807005 hasConceptScore W4285807005C141071460 @default.
• W4285807005 hasConceptScore W4285807005C143998085 @default.
• W4285807005 hasConceptScore W4285807005C197934379 @default.
• W4285807005 hasConceptScore W4285807005C203092338 @default.
• W4285807005 hasConceptScore W4285807005C2775910329 @default.
• W4285807005 hasConceptScore W4285807005C2776694085 @default.
• W4285807005 hasConceptScore W4285807005C2777909004 @default.
• W4285807005 hasConceptScore W4285807005C2778239845 @default.
• W4285807005 hasConceptScore W4285807005C2778375690 @default.
• W4285807005 hasConceptScore W4285807005C2778424827 @default.
• W4285807005 hasConceptScore W4285807005C2778715236 @default.
• W4285807005 hasConceptScore W4285807005C2780352672 @default.
• W4285807005 hasConceptScore W4285807005C509974204 @default.
• W4285807005 hasConceptScore W4285807005C526805850 @default.
• W4285807005 hasConceptScore W4285807005C535046627 @default.
• W4285807005 hasConceptScore W4285807005C71924100 @default.
• W4285807005 hasIssue "1" @default.
• W4285807005 hasLocation W42858070051 @default.
• W4285807005 hasLocation W42858070052 @default.
• W4285807005 hasOpenAccess W4285807005 @default.
• W4285807005 hasPrimaryLocation W42858070051 @default.
• W4285807005 hasRelatedWork W2012557700 @default.
• W4285807005 hasRelatedWork W2029301141 @default.
• W4285807005 hasRelatedWork W2164361265 @default.
• W4285807005 hasRelatedWork W2411104439 @default.
• W4285807005 hasRelatedWork W2598074874 @default.
• W4285807005 hasRelatedWork W2603025253 @default.
• W4285807005 hasRelatedWork W2790413325 @default.

• next